Advertisement
Written by the OrganizedWisdom Team with as the reviewer. All original content is supervised by the The OrganizedWisdom Medical Review Team
medicalnewstoday.com
1 of 0
Medarex, Inc. (Nasdaq: MEDX) announced that it has initiated the Phase 2 clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10 (also known as IP-10),
« Back to the MDX-1100 Rheumatoid Arthritis Drug Shows Promise WisdomCard
Advertisement
This site complies with the HONcode standard for trustworthy health information: verify here.
© 2012 OrganizedWisdom.com, Inc. All rights reserved.
OrganizedWisdom does not provide medical advice, diagnosis or treatment. If you think you
may have a medical emergency, call your doctor or 911 immediately.
As Seen In
